Caribbean Special Report

Jamaica Has the World's Most Famous Cannabis Brand. Now It Wants the Science to Match.

A decade after the island rewrote its drug laws, a cluster of research institutions and licensed companies is trying to convert cultural reputation into something European regulators will actually buy: standardised, lab-backed medical cannabis. The first exports have left. The harder test is consistency at scale.

The Jamaican parliament chose its date carefully. On 6 February 2015, Bob Marley's birthday, it passed the reforms to the Dangerous Drugs Act that would turn decades of prohibition into the starting line for a regulated industry. The symbolism was deliberate, and it points at the central tension in everything that has followed. Jamaica owns the most recognisable cannabis brand on earth. What it has been building since is the far less glamorous machinery needed to sell the product into markets that care about lab certificates, not reputation.

The reforms were ratified on 15 April 2015, a change the then Justice Minister Mark Golding called long overdue. They did more than decriminalise. They activated a research and commercialisation pipeline that had been quietly assembling for years. At its centre sits Medicanja, a Kingston company that has become the public face of Jamaica's ambition to turn botanical heritage into medical products a German or British importer will accept.

Medicanja and the US$15 Million Noble Capital Investment

Medicanja was founded in 2013 by the scientist and entrepreneur Dr Henry Lowe, who unveiled his first medical marijuana products in 2014. The company makes a wide range of cannabis goods spanning nutraceutical, pharmaceutical, cosmeceutical, functional food and even clothing lines. In October 2021 it secured the deal that brought it international notice: a US$15 million injection from Noble Capital, a New York ESG private equity fund. Lowe described it as exactly what the operation needed to scale. Per Tracxn data published in October 2025, that investment makes Medicanja the highest-funded HealthTech company in the Caribbean.

The capital came with expectations attached. Noble Capital projected more than 200 jobs in the short term and over US$10 million in annual exports. Its managing director, Sylvester Gbewonyo Jr., framed the US$15 million as the first part of a planned US$100 million into the Jamaican economy over three years. The deal closed only after more than two years of negotiation, and it installed a new eight-member board chaired by Lowe, then 82. The money was earmarked not just for product but for a vertically integrated facility running everything from cultivation to extraction on a single site.

The Cannabis Licensing Authority and the 2015 Regulatory Framework

The Cannabis Licensing Authority, set up under the 2015 amendments and operational from 2016, sits within the Ministry of Industry, Investment and Commerce. Its job is to regulate the legal cannabis and hemp industry for medical, therapeutic and scientific use, writing the rules for an orderly market while keeping Jamaica compliant with its international obligations. The 2015 changes legalised the handling of ganja for those purposes under licence, covering cultivation, transport, processing and sale.

The Act also softened the everyday picture. Possession of up to two ounces became a petty offence, cultivation of five or fewer plants was permitted, medicinal and sacramental use was protected, and tourists holding medical cannabis licences could apply for permits to buy small amounts. On the quality side, the CLA's management system is certified to ISO 9001:2015, covering its regulatory standards for handling hemp and ganja. In April 2026 the authority went further, launching a Medical Cannabis Special Permit Programme on 16 April aimed at widening access for farmers, retailers and consumers and modernising the licensing framework. The trajectory shows in the numbers: the legal industry was worth USD 63.5 million in 2025, up sharply from USD 38.9 million the year before.

The Science Base: UWI, UTech and the Research Pipeline

The commercial layer sits on a research foundation that has expanded since 2015 unlocked formal academic access to the plant. Both UWI and UTech started cannabis programmes after the reforms. UWI established Jamaica's first legal cannabis plot, growing specific strains to identify their DNA profiles, study how they interact with the human body, work out best cultivation practice and develop products for treating various conditions. Both UWI Mona and UTech were licensed to grow for research under a ministerial order issued through the Dangerous Drugs Act.

The output is starting to look like a genuine science base rather than a press line. UWI researchers have published peer-reviewed work, including studies on the vegetative growth of Cannabis sativa cultivars in Jamaica, and the university is running projects from basic science through pre-clinical and clinical studies. The institutional and commercial worlds overlap closely. Professor Archibald McDonald, then Principal and Pro Vice Chancellor of UWI, attended the launch of Medicanja's first products. UTech, for its part, signed a memorandum of understanding with the California laboratory Steep Hill Labs to share testing methods and pursue joint research, internships and publications, with both universities committing to map the full Jamaican market from law and taxation to seed-to-sale supply chains.

For Medicanja, that bridge between lab and product has been the point from the start. Lowe has highlighted the company's record in basic research, clinical studies and formulation, all delivered quickly while meeting quality standards. The launch of its first 12 products was presented as proof that Jamaica can use science to build healthcare goods. The company says it has more than forty further products and formulas in the pipeline, including clinical trial data on cannabinoid-based drugs for chronic pain management in palliative care.

Export Pathways and the European Opportunity

The investment case is, in large part, an export case. Industry executives have been blunt that the local market is too small to sustain businesses of any real size, which makes export rules essential. Europe is the prize. The European medical cannabis market was worth USD 7.39 billion in 2025 and is projected to reach USD 44.15 billion by 2034, a compound annual growth rate of almost 22 percent. As of August 2025, some form of medical cannabis was legal in 25 European countries.

Jamaica's first verifiable step into regulated international trade came in January 2026. JACANA, a vertically integrated cannabis and wellness company, completed its first medical cannabis export, shipped to the Cayman Islands on 7 January. The shipment moved under a fully regulated bilateral framework, authorised by import permits from the Cayman Islands Chief Medical Officer and an export permit from Jamaica's CLA, with the product reaching patients on prescription through pharmacies and hospitals. JACANA's chief executive, Alexandra Chong, called it validation of a compliant, scalable distribution platform the company intends to deploy across other regulated markets. The export ran under GACP and GMP quality systems. On full export regulations, Jamaica would join roughly only ten countries worldwide with a formal cannabis export regime.

Why Jamaican Medical Cannabis Is Scientifically Distinctive

Jamaica's case does not rest on reputation alone, though the cultural association is globally acknowledged. The scientific argument centres on genetics, growing conditions and the body of domestic research now accumulating. UWI's work on the DNA profiles of local strains underpins the development of standardised, reproducible medical products, which is exactly what import regulators demand. The tropical climate, altitude variation and soil of key growing regions produce cannabinoid and terpene profiles that are geographically specific, aligning with European demand for traceable, naturally cultivated product.

Regulators have leaned into that position, introducing rules that emphasise quality control, consistency and compliance and drawing on guidelines from the global standards body ASTM International. That overlap between research-grade botanical integrity and commercial quality standards is precisely where a company like Medicanja, working from patented formulations developed on locally grown material, has tried to sit. Minister of State Delano Seiveright has framed the industry as a vehicle for economic empowerment, job creation, scientific advancement and social equity. The harder work now is consolidating that ambition into a consistent supply chain and a science base rigorous enough to satisfy importers in Germany, the UK and the other major European markets, where the competitive bar rises every year.

By the Numbers

Read More From Innovation Report

This article is part of the Caribbean Science and Innovation Report. For related coverage of Jamaican science and commercialisation, read our reporting on Jamaica's first metal 3D printer at UTech and on EcoVista, the Caribbean's first university smart city. For more on the region turning natural resources into regulated products, see how a UWI spin-off in Barbados is running cars on sargassum.